Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 10—October 2016
Synopsis

Vaccine-Derived Polioviruses and Children with Primary Immunodeficiency, Iran, 1995–2014

Mohammadreza Shaghaghi1, Shohreh Shahmahmoodi1, Hassan Abolhassani, Saeed Soleyman-jahi, Leila Parvaneh, Sussan Mahmoudi, Zahra Chavoshzadeh, Reza Yazdani, Seyed Mohsen Zahraei, Mohsen Ebrahimi, Mohammad H. Eslamian, Hamideh Tabatabaie, Maryam Yousefi, Yaghoob M. Kandelousi, Aliasghar Oujaghlou, Nima Rezaei, and Asghar AghamohammadiComments to Author 
Author affiliations: Tehran University of Medical Sciences, Tehran, Iran (M. Shaghaghi, S. Shahmahmoodi, H. Abolhassani, S. Soleyman-jahi, L. Parvaneh, M. Ebrahimi, M.H. Eslamian, N. Rezaei, A. Aghamohammadi); Universal Scientific Education and Research Network, Tehran (M. Shaghaghi, H. Abolhassani, S. Soleyman-jahi, R. Yazdani, N. Rezaei, A. Aghamohammadi); Research Center for Immunodeficiences, Tehran (M. Shaghaghi, H. Abolhassani, N. Rezaei, A. Aghamohammadi); Tehran University of Medical Sciences School of Public Health, Tehran (S. Shahmahmoodi, H. Tabatabaie, M. Yousefi, Y.M. Kandelousi, A. Oujaghlou); Ministry of Health and Medical Education, Tehran (S. Mahmoudi, S.M. Zahraei); Shaheed Beheshti Medical University, Tehran (Z. Chavoshzadeh); Isfahan University of Medical Sciences School of Medicine, Isfahan, Iran (R. Yazdani); Children’s Medical Center, Tehran (M. Ebrahimi, M.H. Eslamian)

Main Article

Table 2

Virologic characteristics for 14 patients infected with iVDPV, Iran, 1995–2014*

Patient no. Report year Age, mo, at VAPP onset Virus shedding duration from VAPP onset iVDPV serotype VP1 nt divergence, %† Cleared infection No. contacts‡
1 1995 17.4 8 d 2 2.2 No 0
2 2005 7.5 3 mo 2 1.5 No 6 (all negative)
3 2006 10.6 2 wk 2 1.7 No 8 (all negative)
4 2006 15.1 5 mo 3 2 Yes 7 (all negative)
5 2007 5.3 5 d 2 2 No 8 (all negative)
5 2007 5.3 5 d 1 1.7 No 8 (all negative)
6 2007 20.2 3 d 2 1.2 Yes 5 (all negative)
7 2011 6.2 15 mo 2 2 Yes 22 (21 negative; 1: P3 SL)
8 2011 15.7 3.5 mo 2 3.8 Yes 6 (4 negative; 1: P1 SL; 1: P1 SL and P2 SL)
9 2011 25.2 4 d 2 3.3 No 6 (all negative)
9 2011 25.2 4 d 1 1.6 No 6 (all negative)
10 2012 6.6 1.5 mo 2 2.3 No 0
11 2012 11.4 2 wk 2 1.5 Yes 6 (all negative)
12 2013 13.1 2 wk 2 0.9 No 4 (3 negative; 1: P1 SL)
13 2014 10.0 2.1 mo 1 1.8 Yes 3 (all negative)
14 2014 9.0 3.3 mo 2 0.6 Yes 3 (all negative)

*iVDPV, immunodeficiency-associated vaccine-derived poliovirus; P1, poliovirus type 1; P2, poliovirus type 2; P3, poliovirus type 3; SL, Sabin-like; VAPP, vaccine-associated paralytic poliomyelitis; VP1, viral protein 1.
†Nucleotide divergence from the prototype Sabin strain.
‡No. contacts investigated for VDPVs. Results are indicated in parentheses.

Main Article

1These authors contributed equally to this article.

Page created: September 19, 2016
Page updated: September 19, 2016
Page reviewed: September 19, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external